The mission of the proposed MHIRC is to provide high quality comprehensive infrastructure support for the conduct of intervention research aimed at improving the outcomes for individuals with schizophrenia. The populations that we intend to study range from those who are at high risk for developing the disorder and those recently diagnosed to those with long-term illness and those who are poor or partial responders. Our goals will be clinically meaningful reductions in symptomatology, rates of relapse, adverse effects and substantive improvements in psychosocial and vocational functional and subjective well-being. Our access to a broad range of patients and a full continuum of clinical services will enable us to assess interventions from the long term perspective required by the nature of the illness and the importance of outcomes that go beyond the short term reduction of symptoms. We plan to study treatments in diverse populations using broad inclusion criteria, to maximize generalizability and public health benefit. The Center will enable us to recruit from the expanded mental health network available to us through the recently established N orth Shore- Long Island Jewish Health System from a range of affiliated county, stage and private facilities in the region. The Center also will collaborate with other Centers and investigators on a national level to create synergies that can help advance the field. In addition, the center will serve as a national resource for training, consultation and dissemination of information about the treatment of schizophrenia. The proposed IRC organization includes a central Scientific Direction and Administration Core, and seven units: Clinical Assessment and Training; Biostatistics and Study management; Cognitive Neuroscience; Disability, Outcomes and Cost; Prevention and High Risk; Novel Intervention, Pilot Studies; and Knowledge Transfer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH060575-05
Application #
6758626
Study Section
Special Emphasis Panel (ZMH1-CRB-H (02))
Program Officer
Hsiao, John
Project Start
2000-02-18
Project End
2006-01-31
Budget Start
2004-02-01
Budget End
2006-01-31
Support Year
5
Fiscal Year
2004
Total Cost
$1,381,991
Indirect Cost
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
DeRosse, Pamela; Nitzburg, George C; Kompancaril, Bernie et al. (2014) The relation between childhood maltreatment and psychosis in patients with schizophrenia and non-psychiatric controls. Schizophr Res 155:66-71
Wellington, Robin L; Bilder, Robert M; Napolitano, Barbara et al. (2013) Effects of age on prefrontal subregions and hippocampal volumes in young and middle-aged healthy humans. Hum Brain Mapp 34:2129-40
Kane, John M; Kishimoto, Taishiro; Correll, Christoph U (2013) Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 66:S37-41
Ardekani, Babak A; Tabesh, Ali; Sevy, Serge et al. (2011) Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers. Hum Brain Mapp 32:1-9
Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J et al. (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36:1738-46
Lencz, Todd; Robinson, Delbert G; Napolitano, Barbara et al. (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 20:569-72
Coscia, Denise M; Narr, Katherine L; Robinson, Delbert G et al. (2009) Volumetric and shape analysis of the thalamus in first-episode schizophrenia. Hum Brain Mapp 30:1236-45
Lencz, Todd; Lipsky, Robert H; DeRosse, Pamela et al. (2009) Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry 194:313-8
Szeszko, Philip R; Hodgkinson, Colin A; Robinson, Delbert G et al. (2008) DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 79:103-10
Szeszko, Philip R; Robinson, Delbert G; Ashtari, Manzar et al. (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 33:976-84

Showing the most recent 10 out of 44 publications